The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.

The company’s PD-1 inhibitor Jemperli plus GSK's own PARP Zejula has scored a win in a late-stage endometrial cancer trial that could lead to a key label expansion.

Jemperli has struggled to gain a presence in cancer immunotherapy so far, but GSK believes the PD-1 therapy can hold its own against Merck & Co’s mega-blockbuster Keytruda in a few key areas. 

Bristol and Regeneron sign separate cell therapy technology pacts, plus deals involving Takeda/ImmunoGen, Serina/AgeX, Cybin/Small Pharma, Taiho/Phost’in, Royalty/Ferring and Aardvark/GRI Bio.